A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
Rethinking 3D modelling for a world that generates too much, too quickly.
Updated
January 8, 2026 6:32 PM
A hologram in the franchise Star Wars, in Walt Disney World Resort, Orlando. PHOTO: UNSPLASH
MicroCloud Hologram Inc. (NASDAQ: HOLO), a technology service provider recognized for its holography and imaging systems, is now expanding into a more advanced realm: a quantum-driven 3D intelligent model. The goal is to generate detailed 3D models and images with far less manual effort — a need that has only grown as industries flood the world with more visual data every year.
The concept is straightforward, even if the technology behind it isn’t. Traditional 3D modeling workflows are slow, fragmented and depend on large teams to clean datasets, train models, adjust parameters and fine-tune every output. HOLO is trying to close that gap by combining quantum computing with AI-powered 3D modeling, enabling the system to process massive datasets quickly and automatically produce high-precision 3D assets with much less human involvement.
To achieve this, the company developed a distributed architecture comprising of several specialized subsystems. One subsystem collects and cleans raw visual data from different sources. Another uses quantum deep learning to understand patterns in that data. A third converts the trained model into ready-to-use 3D assets based on user inputs. Additional modules manage visualization, secure data storage and system-wide protection — all supported by quantum-level encryption. Each subsystem runs in its own container and communicates through encrypted interfaces, allowing flexible upgrades and scaling without disrupting the entire system.
Why this matters: Industries ranging from gaming and film to manufacturing, simulation and digital twins are rapidly increasing their reliance on 3D content. The real bottleneck isn’t creativity — it’s time. Producing accurate, high-quality 3D assets still requires a huge amount of manual processing. HOLO’s approach attempts to lighten that workload by utilizing quantum tools to speed up data processing, model training, generation and scaling, while keeping user data secure.
According to the company, the system’s biggest advantages include its ability to handle massive datasets more efficiently, generate precise 3D models with fewer manual steps, and scale easily thanks to its modular, quantum-optimized design. Whether quantum computing will become a mainstream part of 3D production remains an open question. Still, the model shows how companies are beginning to rethink traditional 3D workflows as demand for high-quality digital content continues to surge.